This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group
by Zacks Equity Research
Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.
Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).
Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA
by Zacks Equity Research
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
by Zacks Equity Research
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.
Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth
by Zacks Equity Research
Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.
Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
by Zacks Equity Research
KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
by Zacks Equity Research
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study
by Zacks Equity Research
BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.
Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY
by Kinjel Shah
Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
by Zacks Equity Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
by Zacks Equity Research
The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.
Accenture (ACN) Joins Health Data Collaborative, AI4BetterHearts
by Zacks Equity Research
Accenture's (ACN) goal behind joining the collaborative is to support and advance cardiovascular disease prevention through integrating innovation and emerging technologies.
Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS
by Kinjel Shah
FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
by Zacks Equity Research
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.
The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences
by Zacks Equity Research
Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.